Italy
Updated
Reviewed by Vidhi Upadhyay
Italy PTSD Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Population, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Italy · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Germany at $67.3 Mn.
Russia at 5.9% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$21.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $32.9 Mn | — | — |
| 2025 (base) | $34.7 Mn | +$1.8 Mn | — |
| 2026 (forecast) | $36.5 Mn | +$1.9 Mn | +5.4% |
| 2027 (forecast) | $38.5 Mn | +$2.0 Mn | +11.1% |
| 2028 (forecast) | $40.6 Mn | +$2.1 Mn | +17.1% |
| 2029 (forecast) | $42.8 Mn | +$2.2 Mn | +23.4% |
| 2030 (forecast) | $45.1 Mn | +$2.3 Mn | +30.1% |
| 2031 (forecast) | $47.5 Mn | +$2.4 Mn | +37.1% |
| 2032 (forecast) | $50.1 Mn | +$2.6 Mn | +44.5% |
| 2033 (forecast) | $52.8 Mn | +$2.7 Mn | +52.3% |
| 2034 (forecast) | $55.6 Mn | +$2.9 Mn | +60.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US
$760.0 Mn
China
$132.5 Mn
Japan
$121.1 Mn
Canada
$118.1 Mn
Germany
$67.3 Mn
UK
$42.7 Mn
France
$43.2 Mn
Brazil
$43.9 Mn
Italy (this report)
$34.7 Mn
Ecuador
$33.1 Mn
India
$31.7 Mn
Spain
$29.0 Mn
Saudi Arabia
$29.5 Mn
Mexico
$27.2 Mn
Australia
$22.3 Mn
Russia
$19.0 Mn
New Zealand
$16.5 Mn
South Africa
$11.7 Mn
UAE
$9.5 Mn
Egypt
$4.4 Mn
Philippines
$4.0 Mn
Malaysia
$3.1 Mn
Hong Kong
$2.5 Mn
Singapore
$1.9 Mn
Thailand
$1.9 Mn
Kenya
$1.2 Mn
| Market size, 2025 | $34.7 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $55.6 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 5.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Also called | Post-Traumatic Stress Disorder Treatment |
| Segments | Treatment, population and end user (see all) |
| Key players | Pfizer Inc., Viatris, Lykos Therapeutics, Otsuka Pharmaceutical Co., Ltd., Tonix Pharmaceuticals (see all) |
| Regulator in Italy | AIFASource: Italian Medicines Agency (AIFA). Checked 14 Nov 2026. |
| Active clinical trials | 1 in ItalySource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
PTSD treatment helps people recover from trauma using therapies, medicines and new approaches such as MDMA-assisted therapy.
Key segments of the PTSD Treatment market include treatment (Psychotherapy, SSRIs and SNRIs and Psychedelic-Assisted Therapy) and population (Veterans and Military and Civilians).
More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the PTSD Treatment market. Governments and employers are investing more in mental health care.
Digital tools, new drug classes and care built into primary care and workplaces give the PTSD Treatment market strong room to grow worldwide.
Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the PTSD Treatment market.
The PTSD Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.[2] ClinicalTrials.gov lists 1 study on PTSD Treatment that is recruiting, active or about to start in Italy.[3] Suicide rate: 7.2 per 100,000 people in 2023, the latest WHO figure for Italy.[4]
[1] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
[2] Italian Ministry of Health. Checked 14 Nov 2026.
[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Italy. Retrieved 12 Nov 2026.
[4] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for PTSD Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.
What doctors and scientists are doing in PTSD Treatment right now, from free public sources.
1 active trial in Italy
Recruiting, about to start, or running now.
Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
See every trial on ClinicalTrials.gov (opens in a new tab)7.2 per 100,000 people
Suicide rate, Italy, 2023 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] WHO Global Health Observatory, Suicide rate (per 100,000 people). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
Italy · 2 shared keywords
Italy · 1 shared keyword
Italy · 1 shared keyword
Italy
Italy
Italy
OTC & Nutraceuticals · Italy
Digital Health · Italy
Digital Health · Italy
OTC & Nutraceuticals · Italy
Healthcare Services · Italy
Healthcare Services · Italy
Aurobindo Pharma
Apotex Inc